Five Prime Therapeutics (FPRX) Tops Q1 EPS by 22c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q1 EPS of ($0.49), $0.22 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $5.26 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49